Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

140.59USD
8 Dec 2017
Change (% chg)

$0.58 (+0.41%)
Prev Close
$140.01
Open
$140.00
Day's High
$140.74
Day's Low
$139.90
Volume
1,414,109
Avg. Vol
1,700,858
52-wk High
$144.34
52-wk Low
$109.93

Select another date:

Wed, Dec 6 2017

Photo

Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks from their blood thinner Xarelto.

UPDATE 1-Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

Dec 5 A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks from their blood thinner Xarelto.

CORRECTED-Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

Dec 5 A Philadelphia state court jury on Tuesday ordered Bayer AG and Johnson & Johnson to pay $27.8 million to an Indiana couple over the drugmakers' failure to warn of internal bleeding risks by its blockbuster drug Xarelto.

Idorsia to get $230 million from J&J in latest hypertension deal

ZURICH Idorsia , the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) , will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

Idorsia to get $230 mln from J&J in latest hypertension deal

ZURICH, Dec 4 Idorsia, the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J), will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

Genmab and Johnson & Johnson 'love' partnership as some ponder takeover

LONDON Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion this year and propelled the Danish antibody specialist to the top spot.

UPDATE 1-New vaccine, long-acting drug trials buoy hopes in HIV fight

* Projects backed by U.S. NIH and Gates foundation (Adds details on new drug trial)

J&J drug succeeds in newly diagnosed multiple myeloma patients: study

Johnson & Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.

Johnson & Johnson drug succeeds in newly diagnosed multiple myeloma patients: study

Johnson & Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.

UPDATE 2-J&J drug succeeds in newly diagnosed multiple myeloma patients-study

Nov 21 Johnson & Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.

Select another date: